Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Dr. Brian Durie on Novel Therapies in Multiple Myeloma

January 15th 2013

Brian G. M. Durie, MD, Cedars-Sinai Medical Center, Senior Advisor, Hematologic Malignancies, National Program Director, Multiple Myeloma and Related Disorders for Aptium Oncology, discusses novel therapies for multiple myeloma.

Dr. Zelenetz on the Impact of Rituximab in Lymphoma

January 14th 2013

Andrew D. Zelenetz, MD, PhD, from the Memorial Sloan-Kettering Cancer Center, explains the impact that rituximab has made in the treatment of patients with non-Hodgkin and B-cell lymphomas.

Newly Approved Drugs

January 14th 2013

The FDA approved 11 new hematology-oncology drugs in 2012.

Dr. Cervantes Discusses COMFORT-II Long-Term Data

January 10th 2013

Francisco Cervantes, MD, PhD, Hospital Clinic, IDIBAPS, Barcelona, Spain, discusses the initial and long-term findings of the COMFORT-II trial of ruxolitib for the treatment of myelofibrosis.

Novel Formulations and Molecular Characterization of AML Offer Hope and Complexity

January 10th 2013

Recent advances in the characterization of the molecular genetic defects underlying AML, as well as in novel formulations of therapies, are offering hope for improved outcomes.

How Close Is Close Enough?

January 9th 2013

We have come a long way from the microscope of Galileo, but questions remain in actual practice about how close we need to get to help our patients.

Dr. Hughes on Switching From Imatinib to Nilotinib in CML

January 4th 2013

Timothy P. Hughes, MD, MBBS, explains the two-year follow-up results of the ENESTcmr trial analyzing the switch to nilotinib after at least 2 years on imatinib in patients with chronic phase chronic myeloid leukemia.

Dr. Mark Levis Discusses Quizartinib in AML

January 2nd 2013

Mark J. Levis, MD, PhD, Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, discusses the design and results of a phase II trial of quizartinib in patients with FLT3-ITD positive or negative relapsed/refractory AML.

Ponatinib Could Herald "Revolution" in CML Treatment

December 24th 2012

For the past six years, researchers have been working to develop a treatment for patients with CML who have become resistant to the groundbreaking drug imatinib and to the TKIs dasatinib and nilotinib that were developed subsequently.

Study Results May Change Treatment Standard for Patients Receiving Transplants From Unrelated Donors

December 21st 2012

Patients receiving transplants from unrelated donors to treat various hematologic malignancies may benefit more from receiving adult stem cells harvested from bone marrow rather than peripheral-blood stem cells (the current standard).

Choosing a Tyrosine Kinase Inhibitor in Chronic Myelogenous Leukemia

December 19th 2012

The introduction of tyrosine kinase inhibitors for the treatment of chronic myelogenous leukemia has dramatically changed the course of the disease.

Dr. Wetzler on Autologous Transplantation in Ph+ALL

December 18th 2012

Meir Wetzler, MD, explains the CALGB 10001 study analyzing autologous and allogeneic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia.

Dr. Agnelli Discusses Apixaban for Venous Thromboembolism

December 17th 2012

Giancarlo Agnelli, MD, University of Perugia, Perugia, Italy, discusses the results of a study comparing the efficacy and safety of two doses of apixaban, an oral factor Xa inhibitor, with placebo for the treatment of venous thromboembolism.

Dr. Sung Choi on Vorinostat in GVHD Prevention

December 14th 2012

Sung W. Choi, MD, Assistant Professor, University of Michigan, discusses the results of a phase I/II trial examining the use of the histone deacetylase (HDAC) inhibitor vorinostat in graft-versus-host disease (GVHD) prevention.

Ponatinib Granted Early Approval for Rare Leukemias

December 14th 2012

Acting 3 months ahead of schedule, the FDA approved ponatinib for the treatment of patients with all phases of CML and Ph+ALL that is resistant or intolerant to prior TKIs.

Dr. Cortes on the Phase II Ponatinib PACE Trial

December 12th 2012

Jorge E. Cortes, MD, from the MD Anderson Cancer Center, describes results from a 12 month follow up of the phase II PACE study that examined ponatinib in patients with CML and Ph+ ALL.

Dr. Zelenetz Highlights Studies From the 2012 ASH Meeting

December 11th 2012

Andrew D. Zelenetz, MD, PhD, from Memorial Sloan-Kettering Cancer Center, discusses the trials investigating ABT-199 and ibrutinib that were presented at the 2012 American Society of Hematology (ASH) Meeting.

ASH Campaigns Against Threatened Research Cuts

December 11th 2012

Proposed federal budget cuts that could affect the National Institutes of Health, and thus hematology/oncology research, were highlighted as an area of concern during the 54th Annual Meeting of the American Society of Hematology in Atlanta, Georgia.

The 2012 ASH Annual Meeting

December 11th 2012

Photos from the 54th American Society of Hematology (ASH) Annual Meeting and Exposition, held at the Georgia World Congress Center, Atlanta, GA, from December 8-11, 2012.

Ponatinib Stimulates 'Powerful' Response in Treatment-Resistant Leukemias

December 10th 2012

Researchers have demonstrated that ponatinib can overcome a wide range of mutations that cause treatment resistance-including the stubborn T315I mutation-in all stages of CML and Ph+ ALL.